First Pill Combining New Diabetes Drugs OK’d


The FDA has approved the first combination pill of an SGLT2 inhibitor and a DPP-4 inhibitor, to be marketed as Glyxambi, drugmakers Eli Lilly and Boehringer Ingelheim announced.

The combination of 10 or 25 mg of empagliflozin and 5 mg of linagliptin is approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes.